🚀 go-pugleaf

In misc.health.alternative Matthew A. Emme <emme0002@gold.tc.umn.edu> wrote:
: In article <5hmn3f$qbn$1@nadine.teleport.com> Steve Emerson,
: semerson@teleport.com writes:
: >You can try NADH.  It's new and a completely natural supplement, and
: >a study has found that it relieves Parkinson's symptoms.
: >It's now being used to treat Parkinson's.  



: Most of the recent studies have not been able to verify this.  You might
: want to take a look at  "Treatment of Parkinson's disease with NADH.", by
: Dizdar N; K�agedal B; Lindvall B in the Acta Neurol Scand, 1994 Nov,
: 90:5, 345-7.  

: Can you give me the name of the study that you saw that showed therapy
: with this med works, so I can take a look at it.


   Title
          Nicotinamide adenine dinucleotide (NADH)--a new therapeutic
          approach to Parkinson's disease. Comparison of oral and
          parenteral application.
          
   Author
          Birkmayer JG; Vrecko C; Volc D; Birkmayer W
          
   Address
          Birkmayer-Institut f�r Parkinsontherapie Vienna, Austria.
          
   Source
          Acta Neurol Scand Suppl, 146:1993, 32-5
          
   Abstract
          The reduced coenzyme nicotinamide adenine dinucleotide (NADH)
          has been used as medication in 885 parkinsonian patients in an
          open label trial. About half of the patients received NADH by
          intravenous infusion, the other part orally by capsules. In
          about 80% of the patients a beneficial clinical effect was
          observed: 19.3% of the patients showed a very good (30-50%)
          improvement of disability, 58.8% a moderate (10-30%)
          improvement. 21.8% did not respond to NADH. Statistical
          analysis of the improvement in correlation with the disability
          prior to treatment, the duration of the disease and the age of
          the patients revealed the following results: All these 3
          parameters have a significant although weak influence on the
          improvement. The disability before the treatment has a positive
          regression coefficient (t value < 0.01). The duration of the
          disease has a negative regression coefficient (< 0.01) and so
          has the age a negative regression coefficient (t value < 0.05).
          In other words younger patients and patients with a shorter
          duration of disease have a better chance to gain a marked
          improvement than older patients and patients with longer
          duration of the disease. The orally applied form of NADH
          yielded an overall improvement in the disability which was
          comparable to that of the parenterally applied form.
          

-- 


Steve Emerson     semerson@teleport.com